FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION

被引：1
|
作者：
Sanchez-Garcia, J. [1 ]
Falantes, J. [2 ]
Medina, A. [3 ]
Hernandez-Mohedo, F. [4 ]
Torres-Sabariego, A. [5 ]
Bailen, A. [6 ]
Sole, M.
Casano, J. [1 ]
Calderon, C.
Hermosin, L. [7 ]
Vahi, M. [5 ]
Serrano, J. [1 ]
机构：
[1] Univ Cordoba, Hematol, Reina Sofia Hosp, IMIBIC, Cordoba, Spain
[2] Univ Hosp Virgen Rocio, Hematol, Seville, Spain
[3] Hosp Costa Sol, Hematol, Marbella, Spain
[4] Hosp Costa Sol, Hematol, Granada, Spain
[5] Hosp Virgen Valme, Hematol, Seville, Spain
[6] Hosp Univ Carlos Haya, Hematol, Malaga, Spain
[7] Hosp Jerez, Hematol, Jerez de la Frontera, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30115-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
114
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [41] Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion
    C Stavropoulou
    C Sambani
    H Rigana
    V N Georgakakos
    G Voutsinas
    K N Manola
    G E Pantelias
    V Makropoulos
    Leukemia, 2008, 22 : 1643 - 1646
  • [42] 454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial
    Mossner, M.
    Nowak, D.
    Platzbecker, U.
    Giagounidis, A.
    Goetze, K.
    Letsch, A.
    Haase, D.
    Shimeshan, K.
    Schlenk, R.
    Kohlmann, A.
    Haferlach, T.
    Bug, G.
    Luebbert, M.
    Ganser, A.
    Jann, J-C
    Oblaender, J.
    Fey, S.
    Hofmann, W-K
    Germing, U.
    Nolte, F.
    ONKOLOGIE, 2013, 36 : 126 - 126
  • [43] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Harada, Hironori
    Watanabe, Mitsumasa
    Suzuki, Kenshi
    Yanagita, Soshi
    Suzuki, Takahiro
    Yoshida, Yataro
    Kimura, Akiro
    Tsudo, Mitsuru
    Matsuda, Akira
    Tohyama, Kaoru
    Taniwaki, Masafumi
    Takeshita, Kenichi
    Takatoku, Masaaki
    Ozawa, Keiya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) : 353 - 360
  • [44] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Hironori Harada
    Mitsumasa Watanabe
    Kenshi Suzuki
    Soshi Yanagita
    Takahiro Suzuki
    Yataro Yoshida
    Akiro Kimura
    Mitsuru Tsudo
    Akira Matsuda
    Kaoru Tohyama
    Masafumi Taniwaki
    Kenichi Takeshita
    Masaaki Takatoku
    Keiya Ozawa
    International Journal of Hematology, 2009, 90 : 353 - 360
  • [45] Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment
    Beier, Fabian
    Schneider, Ralph P.
    Buesche, Guntram
    Panse, Jens
    Germing, Ulrich
    Blasco, Maria A.
    Bruemmendorf, Tim H.
    BLOOD, 2012, 120 (21)
  • [46] Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.
    Raza, Azra
    Reeves, James E.
    Feldman, Eric J.
    Deeg, H. Joachim
    Dreisbach, Luke
    Schiffer, Charles A.
    Shammo, Jamile M.
    Klimek, Virginia M.
    Greenberg, Peter L.
    Bennett, John M.
    DeWald, Gordon W.
    Zeldis, Jerome B.
    Wride, Kenton
    Schmidt, Michele
    Knight, Robert D.
    List, Alan F.
    BLOOD, 2006, 108 (11) : 78A - 78A
  • [47] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [48] AXITINIB FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA, FINAL RESULTS FROM A RANDOMIZED PHASE II CLINICAL TRIAL
    Duerinck, J.
    Du Four, S.
    Bouttens, F.
    Verschaeve, V.
    Andre, C.
    Van Fraeyenhove, F.
    Chaskis, C.
    D'haene, N.
    Salmon, I.
    Neyns, B.
    NEURO-ONCOLOGY, 2016, 18 : 41 - 42
  • [49] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
    Schuler, E.
    Schemenau, J.
    Giagounidis, A.
    Haase, D.
    Bueshce, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Luebbert, M.
    Schafhausen, P.
    Bug, G.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
  • [50] Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3trial
    Diez-Campelo, Maria
    Lopez-Cadenas, Felix
    Xicoy, Blanca
    Lumbreras, Eva
    Gonzalez, Teresa
    Gonzalez, Monica del Rey
    Sanchez-Garcia, Joaquin
    Jorda, Rosa Coll
    Slama, Bohrane
    Hernandez-Rivas, Jose-angel
    Thepot, Sylvain
    Bernal, Teresa
    Guerci-Bresler, Agnes
    Bargay, Joan
    Amigo, Maria Luz
    Preudhomme, Claude
    Fenwarth, Laurene
    Platzbecker, Uwe
    Goetze, Katharina S.
    Arar, Ali
    Toribio, Sofia
    Del Canizo, Consuelo
    Hernandez-Rivas, Jesus Maria
    Fenaux, Pierre
    LANCET HAEMATOLOGY, 2024, 11 (09): : e659 - e670
12345